Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

BioSante announces presentation of LibiGel safety update at ENDO 2010

BioSante Pharmaceuticals, Inc., will present a LibiGel safety update at the 2010 Annual Meeting of the Endocrine Society (ENDO), being held from June 19-22, 2010 in San Diego, California.

18 Jun 2010

Obesity linked to bad sexual health: French Study

Now French researchers have found a link between obesity and bad sexual health in their study of 12,364 men and women aged 18 to 69 ranging from normal weight to obese who lived in France in 2006.

17 Jun 2010

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced results from a pre-clinical study showing that calcipotriene 0.005% and betamethasone dipropionate 0.064%, when formulated with NexACT®, results in a topical treatment which shows bioequivalecy in efficacy to Talconex®, one of the leading topical treatments marketed for patients with mild to moderate psoriasis.

16 Jun 2010

Nymox near completion of new NX-1207 follow-up study for BPH

Nymox Pharmaceutical Corporation announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH). Nymox expects to report final results and statistical analysis for the study in the next 1-2 weeks. The new study concerns assessment of the 48-60 month efficacy and benefits of a single treatment of NX-1207.

16 Jun 2010

NexMed provides update on Vitaros NDS with Health Canada

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today provided an update on the status of its New Drug Submission ("NDS") with Health Canada for Vitaros®, the Company's topical treatment for erectile dysfunction.

11 Jun 2010

Therapies for female sexual dysfunction

Many women experience problems in the bedroom at one time or another. Female sexual dysfunction is not uncommon and although some women and healthcare providers have difficulty discussing it, it has been recognized by the medical community for decades. In fact, for the last twenty years, it has been listed in the Diagnostic and Statistical Manual of Mental Disorders, a manual published by the American Psychiatric Association, used to classify and diagnose psychological disorders.

10 Jun 2010

GE Global Research awarded $4M grant to optimize new nerve labeling agent and imaging system

Researchers from GE Global Research announced today that they have been awarded a four-year, $4 million grant from the National Institutes of Health, to optimize a new nerve labeling agent and imaging system. In the future, this agent could help surgeons see delicate nerve endings that are prone to damage during certain procedures, such as prostate surgery.

10 Jun 2010

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the FDA's Office of Orphan Products Development. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the U.S. Orphan drug designation qualifies the sponsor of the product for tax credits and seven years of marketing exclusivity, among other benefits.

7 Jun 2010

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

3 Jun 2010

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive six month data from its double-blind placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH) a bothersome urologic condition that affects the quality of life of more than 50 million men worldwide.

2 Jun 2010

Shionogi Pharma presents study results of PSD502 for treatment of primary PE at AUA 2010

Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., today presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation. These data were presented at the 2010 American Urological Association Annual Meeting in San Francisco.

2 Jun 2010

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that two oral podium presentations on the company's lead candidate, PRX302, will be made at the 2010 Annual Meeting of the American Urological Association (AUA). These presentations will include six month data from the Phase 2b clinical study of PRX302 called TRIUMPH, in patients with moderate to severe benign prostatic hyperplasia (BPH).

1 Jun 2010

Shionogi Pharma presents data on PSD502 pivotal studies for primary premature ejaculation at 2010 AUA

Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., today presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation (PE). These data were presented at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco.

1 Jun 2010

Study measures effects of BPA on male reproductive system

Increasing Bisphenol-A levels in urine are associated with worsening male sexual function, according to a Kaiser Permanente study appearing online in the Journal of Andrology.

28 May 2010

Positive results from 3 year follow-up of BPH patients treated with NX-1207 in Study NX02-0016

Nymox Pharmaceutical Corporation is pleased to report positive new results from the 30-36 month follow-up study of patients treated with NX-1207 in Study NX02-0016. The initial study, completed in the U.S. in 2007, reached statistical significance in Intent-to-Treat Primary Efficacy outcomes at 90 days and 6 months post-treatment with NX-1207 2.5 mg.

26 May 2010

Eli Lilly to honor individuals with Welcome Back Award for improving lives of others

Despite years of debilitating depression, multiple psychiatric hospitalizations and episodes of homelessness, Joseph Rogers refused to let mental illness and an unlucky adolescence blot out his potential imprint on the world. Despite once being branded unemployable, Joseph relishes his role as advocate, embracing the challenges of being a change agent in mental health legislation, and pioneering the peer-run services movement.

21 May 2010

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

BioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line development process, with minimal optimization required.

21 May 2010

New multi-center follow-up study of NX-1207 for treatment of BPH to be completed

19 May 2010

Flibanserin benefits pre-menopausal women with Hypoactive Sexual Desire Disorder

Data from pivotal Phase III clinical trials demonstrate that a higher proportion of pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD) receiving flibanserin 100mg reported both an improvement in their condition and a meaningful benefit from their treatment, compared to placebo.

19 May 2010

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

BioSante Pharmaceuticals, Inc. today announced the receipt of two US new patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,709,224, covers methods for manufacturing recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines.

18 May 2010

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

BioSante announces presentation of LibiGel safety update at ENDO 2010

Obesity linked to bad sexual health: French Study

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

Nymox near completion of new NX-1207 follow-up study for BPH

NexMed provides update on Vitaros NDS with Health Canada

Therapies for female sexual dysfunction

GE Global Research awarded $4M grant to optimize new nerve labeling agent and imaging system

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

Shionogi Pharma presents study results of PSD502 for treatment of primary PE at AUA 2010

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Shionogi Pharma presents data on PSD502 pivotal studies for primary premature ejaculation at 2010 AUA

Study measures effects of BPA on male reproductive system

Positive results from 3 year follow-up of BPH patients treated with NX-1207 in Study NX02-0016

Eli Lilly to honor individuals with Welcome Back Award for improving lives of others

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

New multi-center follow-up study of NX-1207 for treatment of BPH to be completed

Flibanserin benefits pre-menopausal women with Hypoactive Sexual Desire Disorder

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Newsletters you may be interested in